Sopharma AD-Sofia's EBIT per Share for the
three
months ended in Mar. 2026 was zł0.30.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was zł1.21.
During the past 12 months, the average EBIT per Share Growth Rate of Sopharma AD-Sofia was -21.50% per year.
During the past 3 years, the average EBIT per Share Growth Rate was -15.60% per year.
During the past 5 years, the average EBIT per Share Growth Rate was -1.00% per year.
During the past 10 years, the average EBIT per Share Growth Rate was 3.20% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Sopharma AD-Sofia's EBIT per Share or its related term are showing as below:
WAR:SPH'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -15.6 Med: 0.35 Max: 18.1
Current: -15.6
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Sopharma AD-Sofia was 18.10% per year. The lowest was -15.60% per year. And the median was 0.35% per year.
WAR:SPH's 3-Year EBIT Growth Rate is ranked worse than 83.81% of 105
companies
in the Medical Distribution industry
Industry Median: 4.2
vs WAR:SPH: -15.60
Sopharma AD-Sofia (WAR:SPH) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Sopharma AD-Sofia EBIT per Share Related Terms
Sopharma AD-Sofia EBIT per Share Historical Data
* Premium members only.
The historical data trend for Sopharma AD-Sofia's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł1.21
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sopharma AD-Sofia (WAR:SPH) has a EBIT per Share of zł1.21 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sopharma AD-Sofia and its competitors. According to the industry distribution chart, Sopharma AD-Sofia ranks #88 out of 105 companies in the Medical Distribution industry, placing it in the top 83.8%.
Is Sopharma AD-Sofia's EBIT per Share too high?
Sopharma AD-Sofia's current EBIT per Share is zł1.21. Based on the distribution chart, Sopharma AD-Sofia ranks #88 out of 105 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Sopharma AD-Sofia has a GF Score™ of 66/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Sopharma AD-Sofia's EBIT per Share compare to MCK and CAH?
According to the Medical Distribution industry distribution chart, Sopharma AD-Sofia ranks #88 out of 105 companies for EBIT per Share. This places Sopharma AD-Sofia in the lower half of its industry. The industry median EBIT per Share is 4.20. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Distribution company?
The median EBIT per Share among Medical Distribution companies is 4.20, based on 105 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Sopharma AD-Sofia and its competitors. For the Medical Distribution industry, the median EBIT per Share is 4.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sopharma AD-Sofia's current EBIT per Share is zł1.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sopharma AD-Sofia stock overvalued right now?
Based on GuruFocus' analysis, Sopharma AD-Sofia (WAR:SPH) is currently considered Possible Value Trap. The stock's GF Value™ is zł13.47, compared to a current price of zł8.00 — trading 40.6% below its estimated fair value. The current EBIT per Share is zł1.21. Sopharma AD-Sofia's overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Sopharma AD-Sofia (WAR:SPH), the current EBIT per Share is zł1.21 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sopharma AD-Sofia (WAR:SPH) Overvalued in 2026?
Based on GuruFocus' analysis, Sopharma AD-Sofia stock appears to be undervalued.
The current stock price of zł8.00 is trading 40.6% below its estimated GF Value™ of zł13.47.
GuruFocus considers Sopharma AD-Sofia to be Possible Value Trap.
Key valuation signals for WAR:SPH:
EBIT per Share: zł1.21
GF Value™: zł13.47 vs. price of zł8.00 (40.6% below fair value)
No single metric tells the full story. See the WAR:SPH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sopharma AD-Sofia is a company engaged in the production of pharmaceutical products. Its principal activities include the production and trade of medicinal substances and finished drug forms; and research and development as well as engineering and implementation activities in the field of medicinal products. It is also focused on the distribution of pharmaceuticals like medical supplies, sanitary materials, vitamins, food supplements, and cosmetics. The company's segments are the Production of pharmaceutical products; Distribution of pharmaceutical products. It generates the majority of its revenue from the Distribution of pharmaceutical products.
66GF Score
Get the complete analysis for WAR:SPH
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:SPH has been successfully added to your 
